Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
SeaStar Medical Holding Corporation develops extracorporeal medical devices targeting hyperinflammation and organ failure. Its flagship product, the Selective Cytopheretic Device (SCD), modulates immune cells to treat acute and chronic inflammatory conditions, including acute kidney injury, cardiorenal syndrome, and liver failure. The company focuses on regulatory approval, clinical trials, and strategic partnerships to commercialize its innovative, organ-agnostic therapy for critically ill patients worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.